The Signatera research-use-only assay monitors cancer treatment and assesses minimal residual disease, and is customized for individual patients.
Results of the study, published in JAMA, highlight ongoing and future challenges in translating the promise of comprehensive genomics into clinical benefit.
The startup's first test focuses on diagnosing 60 conditions for which treatment is available.
A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.
The Garvan team has shown that whole-genome sequencing can diagnose more cases than targeted panels and is now demonstrating its cost-effectiveness.
The team will use a S$1.5 million grant to develop a database of mutations that cause hereditary breast and gynecological cancers in Asian women.
The WGS workflow for diagnosing pediatric genetic diseases uses off-the-shelf products and fits into standard diagnostic laboratory procedures.
The firm is preparing to launch its first kits and has identified cancer detection and monitoring as well as genotoxicity testing as initial applications.
The firm will work with the FDA to speed the approval process for its liquid biopsy assay, Elio, which analyzes SNVs, amplifications, rearrangements, and MSI.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
An analysis has found that the odds of getting a diagnosis through WES or WGS is 8.3 times greater than it is through chromosomal microarrays.
The genome center will be equipped with five Illumina NovaSeq instruments and will support clinical research at the Immune Therapy and Transplantation Center.
The researchers designed a transcriptome sequencing assay that identifies clinically relevant gene fusions in 541 genes.
Researchers from the French Parkinson's and Movement Disorders Consortium evaluated the diagnostic yield and cost of a 127-gene panel on nearly 400 patients.
The team demonstrated that the approach can yield high sensitivity while maintaining near-perfect specificity, but it must now replicate the early results in a much larger study.
Fifteen years after the Human Genome Project was declared completed, genomic medicine is beginning to be implemented, sooner than Green and others had expected.
A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
Researchers from Stanford University reported in a pilot study that seven RNA transcripts could predict preterm birth.
Researchers found that some molecularly defined subsets of patients responded to targeted drugs while others didn't.
The institutes will explore the use of Inivata's liquid biopsy platform to analyze ctDNA to measure minimal residual disease in NSCLC patients.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.